ScreenerHero

IMVTImmunovant, Inc.

NAS · US · Healthcare · Biotechnology · immunovant.com
44.37USD-1.31%Mkt Cap: 9.16B $P/E: —

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
Immunovant (IMVT) Q1 2027 Earnings Call Transcript

CEO signals multiple pivotal data readouts ahead as cash runway supports IMVT-1402 development.

Motley Fool
Roivant Sciences Q1 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie

MarketBeat
Immunovant, Inc. Q1 2027 Earnings Call Summary

Moby summary of Immunovant, Inc.'s Q1 2027 earnings call

Moby
Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt

MarketBeat
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.

Zacks
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Zacks
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Zacks
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary
Simply Wall St.
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
IInsider Monkey
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
IInsider Monkey